Mark D. Schuman

Schwarz Pharma sought FDA approval to introduce a generic version of a transdermal nitroglycerin patch to treat angina, and was sued for patent infringement under the Hatch-Waxman Act. Following a successful Markman determination and a resulting settlement, Schwarz Pharma was allowed to bring its generic patch to market.